Nephrotoxicity of third-generation, intravenous bisphosphonates

被引：5

作者：

Hirschberg, R ^{[1
]}

机构：

[1] Univ Calif Los Angeles, Harbor Med Ctr, Div Nephrol & Hypertens, Torrance, CA 90509 USA

来源：

TOXICOLOGY | 2004年 / 196卷 / 1-2期

关键词：

D O I：

10.1016/j.tox.2003.11.012

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：165 / 167

页数：3

共 16 条

[1]

Banerjee D, 2003, AM J KIDNEY DIS, V41

[2]

Berenson JR, 2001, CANCER, V91, P1191, DOI 10.1002/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO

[3]

2-0

[4]

BOUNAMEAUX HM, 1983, LANCET, V1, P471

[5] EFFICACY AND SAFETY OF THE BISPHOSPHONATE TILUDRONATE FOR THE TREATMENT OF TUMOR-ASSOCIATED HYPERCALCEMIA [J].

DUMON, JC ;

MAGRITTE, A ;

BODY, JJ .

BONE AND MINERAL, 1991, 15 (03) :257-266

[6]

Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235

[7] The new bisphosphonate, Zometa® (Zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions:: A comparison to pamidronate [J].

Lipton, A ;

Small, E ;

Saad, F ;

Gleason, D ;

Gordon, D ;

Smith, M ;

Rosen, L ;

Kowalski, MO ;

Reitsma, D ;

Seaman, J .

CANCER INVESTIGATION, 2002, 20 :45-54

[8] Toxic acute tubular necrosis following treatment with zoledronate (Zometa) [J].

Markowitz, GS ;

Fine, PL ;

Stack, JI ;

Kunis, CL ;

Radhakrishnan, J ;

Palecki, W ;

Park, J ;

Nasr, SH ;

Hoh, S ;

Siegel, DS ;

D'Agati, VD .

KIDNEY INTERNATIONAL, 2003, 64 (01) :281-289

[9]

Markowitz GS, 2001, J AM SOC NEPHROL, V12, P1164, DOI 10.1681/ASN.V1261164

[10] Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma [J].

Menssen, HD ;

Sakalová, A ;

Fontana, A ;

Herrmann, Z ;

Boewer, C ;

Facon, T ;

Lichinitser, MR ;

Singer, CRJ ;

Euller-Ziegler, L ;

Wetterwald, M ;

Fiere, D ;

Hrubisko, M ;

Thiel, E ;

Delmas, PD .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (09) :2353-2359

← 1 2 →